结直肠癌早筛、早诊、早治上海方案(2023年版)

上海市抗癌协会大肠癌专业委员会

  • 收稿日期:2023-11-24 修回日期:2023-12-06 出版日期:2024-01-30 发布日期:2024-02-05

摘要/Abstract

摘要:

结直肠癌是中国常见的恶性肿瘤,目前中国结直肠癌发病率和死亡率呈不断上升趋势,在中国全部恶性肿瘤中发病率位居第2位、死亡率位居第4位,已成为严重威胁人类生命健康的公共卫生问题。大量的研究和实践表明,结直肠癌早筛、早诊、早治是降低结直肠癌患者死亡率的有效措施。上海市自2013年起,持续开展社区结直肠癌筛查,通过早期筛查发现癌前病变、降低发病风险,早期诊断结直肠癌并进行及时治疗,显著延长了结直肠癌患者的生存期。同时,上海市各大医院规范化诊治水平较高,结直肠癌患者5年生存率也相对较高,甚至超过欧美发达国家。但由于地区差异和经济发展的不平衡,中国大部分地区仍未开展结直肠癌相关防治项目,同时,由于基层医院业务能力不足,较低的早期诊断率及早期治疗率成为限制中国结直肠癌患者预后进一步提高的瓶颈。针对基层医院对于结直肠癌背景、风险预防、常用筛查手段、规范性诊断和治疗等方面认知不足的现状,上海市抗癌协会大肠癌专业委员会组织上海各大医院结直肠癌诊治专家,共同编写《结直肠癌早筛、早诊、早治上海方案(2023年版)》,方案从结直肠癌的流行病学、危险因素及保护因素、癌前病变及早期结直肠癌、筛查、早期结直肠癌的诊断和早期结直肠癌的治疗等6个方面进行了详尽介绍,并提供了相关建议供临床医师参考。本方案旨在规范结直肠癌筛查与早诊、早治实践,提升中国结直肠癌的防治效果。结直肠癌的早筛、早诊、早治是提高患者生存率和改善患者预后的关键。目前,结直肠癌虽然已有多种筛查方法,但仍存在灵敏度和特异度不足等问题,同时在全国众多医院,结直肠癌的诊断和治疗还存在着规范化的问题。因此,未来结直肠癌防治之路除了开发更高效的筛查方法、提高早期诊断准确率及探索更安全有效的治疗方法外,还需要在诊断和治疗上为基层医院提供帮扶,强调结直肠癌的诊断和治疗规范化,提高基层医师的诊治水平,提升基层医院的诊治能力,最后还应加强公众健康教育,提高公众对结直肠癌的认知和预防意识。

关键词: 结直肠癌, 早筛, 早诊, 早治

Abstract:

Colorectal cancer is a common malignant tumor in China. At present, the incidence rate and the mortality rate of colorectal cancer in China are on the rise. Among all malignant tumors in China, the incidence rate of colorectal cancer ranks second, and the mortality rate ranks fourth. It has become a public health problem that seriously threatens our health. A large number of studies and practice have shown that colorectal cancer screening, early diagnosis and treatment are effective measures to reduce the mortality rate of colorectal cancer in the population. Since 2013, Shanghai has continued to carry out community colorectal cancer screening, which greatly extends the survival period of colorectal cancer patients by early detection of precancerous lesions, reducing the risk of disease, early diagnosis of colorectal cancer and timely treatment. At the same time, the standardized diagnosis and treatment level of major hospitals in Shanghai is relatively high, and the 5-year survival rate of colorectal cancer patients is also relatively high, even exceeding that of the developed countries in Europe and America. However, due to regional differences and uneven economic development, most regions in China have not yet carried out colorectal cancer-related prevention and treatment projects. At the same time, due to the lack of clinical service capacity of primary hospitals, the low early diagnosis and early treatment rates have become a bottleneck restricting the further improvement of the prognosis of colorectal cancer patients in China. In response to the current situation of insufficient clinical service capabilities in primary hospitals in terms of colorectal cancer-related knowledge, risk prevention knowledge, common screening methods, standardized diagnosis, treatment knowledge, etc., the Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association organized colorectal cancer diagnosis and treatment experts from major hospitals in Shanghai to jointly compile the “Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition)”. The plan introduced the epidemiology of colorectal cancer, risk factors and protective factors of colorectal cancer, precancerous lesions of colorectal cancer and early colorectal cancer, screening of colorectal cancer, diagnosis of early colorectal cancer and treatment of early colorectal cancer, and provided relevant suggestions for clinical reference. The protocol aimed to standardize the screening, early diagnosis and early treatment practice of colorectal cancer, and improve the prevention and treatment of colorectal cancer in China. Early screening, diagnosis and treatment of colorectal cancer are keys to improving patient survival rates and prognosis. Currently, although there are various screening methods for colorectal cancer, there are still problems of insufficient sensitivity and specificity. At the same time, in many hospitals across the country, there are also problems of standardization in the diagnosis and treatment of colorectal cancer. Therefore, in the future, in addition to developing more efficient screening methods, improving the accuracy of early diagnosis and exploring safer and more effective treatment methods, the prevention and treatment of colorectal cancer also requires providing assistance to primary hospitals in diagnosis and treatment, emphasizing the standardization of colorectal cancer diagnosis and treatment, improving the diagnosis and treatment level of primary doctors, enhancing the diagnosis and treatment abilityies of primary hospitals and finally strengthening public health education to improve public awareness of colorectal cancer and prevention.

Key words: Colorectal cancer, Early screening, Early diagnosis, Early treatment

中图分类号: 

相关文章

[1] 周聪, 何丽娜, 成小姣, 黄廷磊, 涂水平. RSPO3抑制体内结直肠癌移植瘤生长和增加NK细胞浸润的作用研究[J]. 中国癌症杂志, 2023, 33(7): 664-672.
[2] 冶俊玲, 郑小影, 郭新建, 陈瑞慧, 杨柳, 苟笑丹, 蒋汉梅. LncRNA SNHG5/miR-26a-5p/MTDH信号轴促进结直肠癌转移的机制研究[J]. 中国癌症杂志, 2023, 33(7): 673-685.
[3] 蔡家洛, 朱锐秋, 李森, 曹亦军, 黄坊. 炎症癌相关成纤维细胞介导结直肠癌细胞耐药的机制研究[J]. 中国癌症杂志, 2023, 33(12): 1065-1072.
[4] 陈玺, 曾晓颖, 陈佳艳, 刘菲, 唐曦. 错配修复蛋白联合血清肿瘤标志物与Ki-67增殖指数对结直肠癌预后的临床价值[J]. 中国癌症杂志, 2022, 32(3): 243-250.
[5] 王乾, 张静, 郁成礼, 包龙龙, 蔡旭, 蒋文华, 黄丹, 盛伟琪, 朱晓丽, 周晓燕, 柏乾明. 全自动IdyllaTM系统在中国结直肠癌微卫星不稳定性检测中的可行性研究[J]. 中国癌症杂志, 2022, 32(11): 1084-1090.
[6] 贾真真, 何双, 李扬扬, 温菲菲, 许晓阳, 郭宁杰, 吴淑华. 结直肠癌中DPD与LC3、P62表达的相关性及其临床意义[J]. 中国癌症杂志, 2022, 32(1): 24-33.
[7] 马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[8] 张迎强, 林岩松 . 90 Y微球选择性内放射治疗在结直肠癌肝转移中的应用及研究进展[J]. 中国癌症杂志, 2021, 31(8): 762-768.
[9] 花 晴, 申雪芳, 许平波. KLK8通过调节EGF对结直肠癌细胞凋亡的影响及其机制[J]. 中国癌症杂志, 2021, 31(5): 383-389.
[10] 马维东, 王彤彤, 朱启航, 杨海鸥, 林 丹. 外泌体中circ_0044366调控肿瘤相关成纤维细胞MMP2的表达促进结直肠癌转移的机制研究[J]. 中国癌症杂志, 2021, 31(5): 397-407.
[11] 陈馨宁, 黄 斐, 沈敏娜, 杨轶慧, 王蓓丽, 郭 玮 . 转移性结直肠癌患者ctDNA基因突变检测方法的比较及影响因素分析[J]. 中国癌症杂志, 2021, 31(3): 192-197.
[12] 陈飞儿 , 张 凤 , 谈振宇 , 夏庆华 , 包士三 , 陶 琨 , 董志恒 . 白细胞介素35和白细胞介素37与结直肠癌临床病理学特征及预后的相关性研究[J]. 中国癌症杂志, 2020, 30(6): 456-461.
[13] 吴春晓 , 顾 凯 , 龚杨明 , 郑荣寿 , 王少明 , 陈 茹 , 张思维 , 施 燕 , 魏文强 , 付 晨 , 赫 捷 . 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020, 30(4): 241-245.
[14] 开今言 , 马 倩 , 童 颖 , 谢素红 , 何成彦 , 宋丽娜 , 孙 静 , 朱广博 , 卢仁泉 , 郭 林 . 血清纤维蛋白降解复合物(DR-70)检测在结直肠癌患者中的诊断价值[J]. 中国癌症杂志, 2020, 30(4): 293-298.
[15] 朱小坚, 林 康, 卜凡钦, 骆  晨, 黄 超, 朱正明. DJ-1的高表达通过cyclin D1/p53-MDM2-AKT途径促进结直肠癌细胞的增殖、侵袭[J]. 中国癌症杂志, 2020, 30(3): 208-216.